RankingsPricing
  1. US-listed companies
  2. MoonLake Immunotherapeutics
  3. Raw

MoonLake ImmunotherapeuticsMLTX

Market cap
$895.64M
P/E ratio
SummaryFinancials
Back to summarized table
Dec 31,
2020		Dec 31,
2021		Dec 31,
2022		Dec 31,
2023		Dec 31,
2024
Net loss---64,506,051-44,079,117-121
Depreciation and amortization----1
Share-based compensation expense--1077
Pension Expense (Reversal of Expense), Noncash--304,031-85,2541,300
Other non-cash items---68,454-484,762227,012
Other receivables--68,355839,7332
Operating lease right-of-use assets---65,5135,445
Prepaid expenses283,057-156,1413613
Trade and other payables---1,314,31827
Operating lease liabilities----222,259-1,423,163
Accrued expenses and other current liabilities--3-326,7255
Net cash flow used in operating activities-316,692-611,071-55,893,900-42,778,167-116,587,263
Purchase of short-term marketable debt securities--42176350
Proceeds from maturities of short-term marketable debt securities--10151145
Purchase of property and equipment--16,009284,634519,520
Net cash flow used in investing activities-115,000,000--32,340,593-25,184,324-205,595,299
Proceeds from Issuance Initial Public Offering---48253
Stamp duty on capital injection from MoonLake to MoonLake AG---31
Proceeds from Stock Options Exercised----242,004
Proceeds from Business Combination--135--
Contribution for par value of Class V Shares--42,935--
Repayment of loan liability--15--
Buyback of unvested MoonLake AG Common Shares by MoonLake AG following an employee contract termination----50
Net cash flow provided by financing activities117-58,06312048051
Effect of movements in exchange rates on cash held--8,540-75,307127,966
Net change in cash and cash equivalents--31412-270,742,888
Income Taxes Paid, Net--4,31241,713147,294
Right-of-Use Asset Obtained in Exchange for Operating Lease Liability--435,0054554,857